During severe exacerbations, asthmatic children vary significantly in their response to high-dose continuous β2-adrenergic receptor (ADRβ2) agonist therapy. Genetic polymorphisms have been identified within the ADRβ2 that may be functionally relevant, but few studies have been performed in this population. Our hypothesis was that genotypic differences are associated with magnitude of response to ADRβ2 agonist treatment during severe asthma exacerbations in children.Methods
Children aged 2–18 years admitted to the ICU (intensive care unit) with a severe asthma exacerbation between 2006 and 2008 were eligible. Genotyping of the ADRβ2 was performed.Results
Eighty-nine children consented and were enrolled. Despite similar clinical asthma scores on admission, children with the Gly16Gly genotype at amino acid position 16 had significantly shorter ICU length of stay (LOS) and hospital LOS, compared to children with Arg16Arg and Arg16Gly genotypes. Children with either the Gln27Glu or Glu27Glu genotype at amino acid position 27 also had significantly shorter ICU LOS and hospital LOS compared to children with the Gln27Gln genotype. The Arg16Gly-Gln27Gln haplotype was associated with the longest ICU LOS, but this was not statistically different from other haplotypes.Conclusions
In this cohort of children with severe asthma exacerbations, ADRβ2 polymorphisms were associated with responses to therapy. Knowledge of the genetic profile of children with asthma may allow for targeted therapy during acute exacerbations. Pediatr Pulmonol. 2012; 47:233–239. © 2011 Wiley Periodicals, Inc.